Coprococcus

The first correction is simple: this page is about Coprococcus eutactus, not every species in the Coprococcus genus. Most human research reports genus-level Coprococcus or nearby species such as C. catus and C. comes. Those studies are useful, but they are not the same measurement as a stool C. eutactus result.

This is an exploratory microbiome marker. No clinical society uses C. eutactus abundance to diagnose fatty liver, inflammatory bowel disease, small intestinal bacterial overgrowth, or colorectal cancer. Labs usually compare your result with their own reference group, and results from different labs may not line up.

What This Species Does

C. eutactus belongs to Lachnospiraceae, a family that includes many fiber fermenters in the human colon. It can make butyrate and acetate from carbohydrates that you do not digest yourself. Butyrate is a small fat your colon lining can burn for fuel.

C. eutactus is unusual because it carries genes for two butyrate-making routes, although the clearest laboratory demonstration of both routes came from a closely related Coprococcus strain rather than from C. eutactus itself. Either way, a high result is not automatically good. It means this species is part of the colon's fermentation machinery, and the meaning of the number depends on symptoms, the rest of the stool panel, diet, medication use, and sample quality.

One technical point matters a lot: most stool microbiome reports show relative abundance. That is the share of the stool community made up by this organism. If another group expands, your C. eutactus percentage can fall even if the actual number of cells did not.

Fatty Liver Disease

The strongest disease signal is genus-level, not species-specific. A meta-analysis pooling 15 case-control studies with 1,265 people found Coprococcus lower in people with nonalcoholic fatty liver disease than in healthy controls. The same pattern appeared alongside lower Faecalibacterium and Ruminococcus, two other fiber-fermenting groups.

A separate 54-study review covering 8,894 participants reached a similar broad conclusion: people with fatty liver often show fewer anti-inflammatory, fiber-fermenting microbes, including Coprococcus. This does not prove C. eutactus itself is low in every person with fatty liver, and it does not show that raising it treats liver fat.

If your result is low and fatty liver is plausible, central weight gain, insulin resistance, high triglycerides, or elevated liver enzymes, check the liver directly. ALT, AST, GGT, insulin resistance markers, and imaging answer that question better than a single stool organism can.

Bacterial Overgrowth and Symptoms

The small-intestinal-overgrowth data are easy to overread. One 154-person study measured Coprococcus_2, a related genus-level group rather than C. eutactus alone. Coprococcus_2 was higher in symptomatic people with positive breath tests and tracked with distension, abdominal pain, diarrhea, and constipation scores.

The same paper included a berberine treatment validation set. In people whose breath test turned negative, Coprococcus fell from about 1.09% of the community to 0.18%. In people whose treatment failed, it barely moved. That is interesting, but it is still a related measurement, not proof that a high C. eutactus result diagnoses overgrowth.

This is the part most people get backwards. A fiber fermenter can be helpful in the colon and still be part of a gas-producing pattern when the wrong microbes are active in the wrong place. If you are bloated after meals, the next test is a hydrogen-methane breath test, not a conclusion from C. eutactus alone.

Inflammation and Other Conditions

Reduced Coprococcus also appears in some inflammatory conditions. In a small study of people with psoriatic arthritis and skin psoriasis, genus-level Coprococcus was lower than in healthy controls, and fecal hexanoate and heptanoate were lower too. That was not a C. eutactus-specific finding.

Inflammatory bowel disease studies point in more than one direction depending on the cohort and the taxonomic level. Some multi-omic work flags C. comes and other Lachnospiraceae as part of the disease pattern. Other cohorts find different Coprococcus species enriched. A stool line item at the species level cannot carry all that context by itself.

The COVID-19 data show why species names matter. In one hospitalized cohort, C. catus, a related but different species, was enriched in critically ill patients. That does not make C. eutactus harmful. It shows that genus-level good-bug language breaks down fast.

Correlation Is Most of the Evidence

Most microbiome findings are observational. They can show that people with a condition carry different bacteria. They cannot tell you whether the bacteria came first, or whether diet, medication, transit time, inflammation, and the disease itself reshaped the stool pattern.

Genetics-based studies do not settle it. One Mendelian randomization analysis found genetically predicted Coprococcus was negatively associated with longevity. That does not prove C. eutactus shortens life. The exposure was genus-level, and the inherited variants used in the analysis can affect traits besides the bacteria.

So read this result as ecology. It tells you something about a stool sample. It does not give a verdict on your health.

Why a Single Reading Can Fool You

Day-to-day variation is large. In a daily-sampling study of quantitative gut profiles, 78% of microbial genera varied more within one person over time than between different people. A separate two-year metagenomic study found better stability, with median reliability around 0.7 at the genus level, but that still leaves real movement.

• Relative abundance: if another organism expands, the C. eutactus share can fall even when the actual amount did not.
• Stool consistency and transit time: looser or faster-moving stool shifts community composition, so a rough gut week can distort the result.
• Blood in the stool: occult blood lowered measured C. eutactus and C. catus in people without cancerous or precancerous lesions.
• Lab processing: DNA extraction and freezing protocols can change measured microbiome diversity, so two labs can report different numbers from the same stool.
• Recent antibiotics: repeated courses can reshape the fecal microbiome for months. A sample taken soon after antibiotics is not your steady state.

What to Do With an Out-of-Pattern Result

Read the number with symptoms and the rest of the panel. Alone, it is too small a lens.

If your level is high and you have bloating, distension, or pain after meals, consider a hydrogen-methane breath test. Breath testing is imperfect because positive tests can occur in people without symptoms, but it is the right workup for suspected overgrowth. A gastroenterologist belongs in the loop when symptoms are persistent or treatment decisions are not straightforward.

If your level is low, look for a pattern. Low C. eutactus alongside low Faecalibacterium and low butyrate suggests a broader loss of fiber fermenters. Fecal calprotectin helps separate active gut inflammation from irritable bowel patterns. Liver enzymes and metabolic markers are the better follow-up if fatty liver is the concern.

This result does not replace validated screening. If colorectal cancer is the worry, because of symptoms, age, or family history, use colonoscopy or a fecal immunochemical test. Microbiome-based colorectal cancer models exist, but they use multi-marker classifiers. A single C. eutactus result has not been validated for that job.